{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:37:11Z","timestamp":1788827831414,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019229","name":"Viewray","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019229","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Celgene\/SAKK Life Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy is a well-established local treatment option but there is some evidence for a better and longer pain response after a dose-intensified radiotherapy of the primary pancreatic cancer (pPCa). Stereotactic body radiation therapy (SBRT) can deliver high radiation doses in few fractions, therefore reducing chemotherapy-free intervals. However, prospective data on pain control after SBRT of pPCa is very limited. Therefore, we aim to investigate the impact of SBRT on pain control in patients with mPDAC in a prospective trial.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a prospective, double-arm, randomized controlled, international multicenter study testing the added benefit of MR-guided adaptive SBRT of the pPca embedded between standard of care-chemotherapy (SoC-CT) cycles for pain control and prevention of pain in patients with mPDAC. 92 patients with histologically proven mPDAC and at least stable disease after initial 8\u00a0weeks of SoC-CT will be eligible for the trial and 1:1 randomized in 3 centers in Germany and Switzerland to either experimental arm A, receiving MR-guided SBRT of the pPCa with 5\u2009\u00d7\u20096.6\u00a0Gy at 80% isodose with continuation of SoC-CT thereafter, or control arm B, continuing SoC-CT without SBRT. Daily MR-guided plan adaptation intents to achieve good target coverage, while simultaneously minimizing dose to organs at risk. Patients will be followed up for minimum 6 and maximum of 18\u00a0months. The primary endpoint of the study is the \u201cmean cumulative pain index\u201d rated every 4\u00a0weeks until death or end of study using numeric rating scale.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>An adequate long-term control of pain symptoms in patients with mPDAC is an unmet clinical need. Despite improvements in systemic treatment, local complications due to pPCa remain a clinical challenge. We hypothesize that patients with mPDAC will benefit from a local treatment of the pPCa by MR-guided SBRT in terms of a durable pain control with a simultaneously favorable safe toxicity profile translating into an improvement of quality-of-life.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>German Registry for Clinical Trials (DRKS): DRKS00025801.\u00a0Meanwhile the study is also registered at ClinicalTrials.gov with the\u00a0Identifier: NCT05114213.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-01988-6","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T05:30:50Z","timestamp":1643088650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-6152","authenticated-orcid":false,"given":"M.","family":"Pavic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vornh\u00fclz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Al Tawil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mayerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"issue":"1","key":"1988_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1988_CR2","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/cam4.767","volume":"5","author":"AS Quante","year":"2016","unstructured":"Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649\u201356.","journal-title":"Cancer Med"},{"issue":"1","key":"1988_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10\u201327.","journal-title":"World J Oncol"},{"issue":"1","key":"1988_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.currproblcancer.2018.01.013","volume":"42","author":"AR Lewis","year":"2018","unstructured":"Lewis AR, Pihlak R, McNamara MG. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer. 2018;42(1):26\u201339.","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"1988_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.15403\/jgld.2014.1121.252.pcr","volume":"25","author":"G Lakatos","year":"2016","unstructured":"Lakatos G, Bal\u00e1zs A, Kui B, G\u00f3di S, Sz\u00fccs \u00c1, Szentesi A, et al. Pancreatic cancer: multicenter prospective data collection and analysis by the Hungarian Pancreatic Study Group. J Gastrointest Liver Dis JGLD. 2016;25(2):219\u201325.","journal-title":"J Gastrointest Liver Dis JGLD"},{"issue":"4","key":"1988_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.21873\/anticanres.14133","volume":"40","author":"I Lohse","year":"2020","unstructured":"Lohse I, Brothers SP. Pathogenesis and treatment of pancreatic cancer related pain. Anticancer Res. 2020;40(4):1789\u201396.","journal-title":"Anticancer Res"},{"issue":"12","key":"1988_CR7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1055\/s-0033-1356220","volume":"51","author":"T Seufferlein","year":"2013","unstructured":"Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol. 2013;51(12):1395\u2013440.","journal-title":"Z Gastroenterol"},{"key":"1988_CR8","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma2021 22.06.2021; Version 2.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 10 July 2021."},{"issue":"19","key":"1988_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"1988_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"3","key":"1988_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000439523","volume":"92","author":"M Schober","year":"2015","unstructured":"Schober M, Javed MA, Beyer G, Le N, Vinci A, Sund M, et al. New advances in the treatment of metastatic pancreatic cancer. Digestion. 2015;92(3):175\u201384.","journal-title":"Digestion"},{"key":"1988_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.critrevonc.2016.01.006","volume":"99","author":"A Kristensen","year":"2016","unstructured":"Kristensen A, Vagnildhaug OM, Gr\u00f8nberg BH, Kaasa S, Laird B, Solheim TS. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Crit Rev Oncol Hematol. 2016;99:286\u201398.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1988_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/bjs.9716","volume":"102","author":"SJE Rombouts","year":"2014","unstructured":"Rombouts SJE, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch ORC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg. 2014;102(3):182\u201393.","journal-title":"Br J Surg"},{"issue":"3","key":"1988_CR14","first-page":"Cd007519","volume":"2011","author":"PG Arcidiacono","year":"2011","unstructured":"Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011;2011(3):Cd007519.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1988_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/pme.12176","volume":"14","author":"W Nagels","year":"2013","unstructured":"Nagels W, Pease N, Bekkering G, Cools F, Dobbels P. Celiac plexus neurolysis for abdominal cancer pain: a systematic review. Pain Med (Malden, Mass). 2013;14(8):1140\u201363.","journal-title":"Pain Med (Malden, Mass)"},{"issue":"3","key":"1988_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.21037\/apm.2018.10.02","volume":"8","author":"TC Lam","year":"2019","unstructured":"Lam TC, Tseng Y. Defining the radiation oncologist\u2019s role in palliative care and radiotherapy. Ann Palliat Med. 2019;8(3):246\u201363.","journal-title":"Ann Palliat Med"},{"issue":"6","key":"1988_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3892\/mco.2016.851","volume":"4","author":"E Wolny-Rokicka","year":"2016","unstructured":"Wolny-Rokicka E, Sutkowski K, Grz\u0105dziel A, Dorsz \u017b, Tukiendorf A, Lipi\u0144ski J, et al. Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: a retrospective analysis of single-institutional experiences. Mol Clin Oncol. 2016;4(6):1088\u201392.","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"1988_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/0284186X.2017.1400692","volume":"57","author":"G Ebrahimi","year":"2018","unstructured":"Ebrahimi G, Rasch CRN, van Tienhoven G. Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the Academic Medical Center (AMC) experience. Acta Oncol (Stockh, Swed). 2018;57(5):697\u2013700.","journal-title":"Acta Oncol (Stockh, Swed)"},{"key":"1988_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13014-014-0312-5","volume":"10","author":"Z Wang","year":"2015","unstructured":"Wang Z, Ren ZG, Ma NY, Zhao JD, Zhang Z, Ma XJ, et al. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Radiat Oncol (Lond, Engl). 2015;10:14.","journal-title":"Radiat Oncol (Lond, Engl)"},{"issue":"12","key":"1988_CR20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/0360-3016(81)90185-1","volume":"7","author":"R Whittington","year":"1981","unstructured":"Whittington R, Dobelbower RR, Mohiuddin M, Rosato FE, Weiss SM. Radiotherapy of unresectable pancreatic carcinoma: a six year experience with 104 patients. Int J Radiat Oncol Biol Phys. 1981;7(12):1639\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1988_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/cncr.26365","volume":"118","author":"JD Murphy","year":"2012","unstructured":"Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 2012;118(4):1119\u201329.","journal-title":"Cancer"},{"issue":"2","key":"1988_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","volume":"97","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1988_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MEG.0000000000000283","volume":"27","author":"JC Lin","year":"2015","unstructured":"Lin JC, Jen YM, Li MH, Chao HL, Tsai JT. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer. Eur J Gastroenterol Hepatol. 2015;27(3):259\u201364.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"1988_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cncr.29161","volume":"121","author":"JM Herman","year":"2015","unstructured":"Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128\u201337.","journal-title":"Cancer"},{"issue":"23","key":"1988_CR25","doi-asserted-by":"publisher","first-page":"16427","DOI":"10.18632\/oncotarget.24713","volume":"9","author":"JF Ryan","year":"2018","unstructured":"Ryan JF, Rosati LM, Groot VP, Le DT, Zheng L, Laheru DA, et al. Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Oncotarget. 2018;9(23):16427\u201336.","journal-title":"Oncotarget"},{"key":"1988_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1748-717X-8-240","volume":"8","author":"CH Kim","year":"2013","unstructured":"Kim CH, Ling DC, Wegner RE, Flickinger JC, Heron DE, Zeh H, et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiat Oncol (Lond, Engl). 2013;8:240.","journal-title":"Radiat Oncol (Lond, Engl)"},{"key":"1988_CR27","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2147\/JPR.S167994","volume":"11","author":"M Buwenge","year":"2018","unstructured":"Buwenge M, Macchia G, Arcelli A, Frakulli R, Fuccio L, Guerri S, et al. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. J Pain Res. 2018;11:2169\u201378.","journal-title":"J Pain Res"},{"issue":"1","key":"1988_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","volume":"31","author":"S Gourgou-Bourgade","year":"2013","unstructured":"Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1988_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s43441-019-00063-9","volume":"54","author":"CH Mallinckrodt","year":"2020","unstructured":"Mallinckrodt CH, Bell J, Liu G, Ratitch B, O\u2019Kelly M, Lipkovich I, et al. Aligning estimators with estimands in clinical trials: putting the ICH E9(R1) guidelines into practice. Ther Innov Regul Sci. 2020;54(2):353\u201364.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"1988_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0962280212445800","volume":"23","author":"D Rizopoulos","year":"2014","unstructured":"Rizopoulos D, Lesaffre E. Introduction to the special issue on joint modelling techniques. Stat Methods Med Res. 2014;23(1):3\u201310.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"1988_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65\u201374.","journal-title":"N Engl J Med"},{"issue":"4","key":"1988_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.pan.2018.04.008","volume":"18","author":"AM Drewes","year":"2018","unstructured":"Drewes AM, Campbell CM, Ceyhan GO, Delhaye M, Garg PK, van Goor H, et al. Pain in pancreatic ductal adenocarcinoma: a multidisciplinary, International guideline for optimized management. Pancreatology. 2018;18(4):446\u201357.","journal-title":"Pancreatology"},{"issue":"2","key":"1988_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0148607113502674","volume":"38","author":"X H\u00e9buterne","year":"2014","unstructured":"H\u00e9buterne X, Lemari\u00e9 E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38(2):196\u2013204.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"2","key":"1988_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12029-016-9909-2","volume":"49","author":"JW Lischalk","year":"2018","unstructured":"Lischalk JW, Burke A, Chew J, Elledge C, Gurka M, Marshall J, et al. Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer. J Gastrointest Cancer. 2018;49(2):116\u201323.","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"1988_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.prro.2020.02.010","volume":"10","author":"AJ Koong","year":"2020","unstructured":"Koong AJ, Toesca DAS, Baclay JRM, Pollom EL, von Eyben R, Koong AC, et al. The utility of stereotactic ablative radiation therapy for palliation of metastatic pancreatic adenocarcinoma. Pract Radiat Oncol. 2020;10(4):274\u201381.","journal-title":"Pract Radiat Oncol"},{"issue":"10","key":"1988_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s11605-010-1323-7","volume":"14","author":"MS Didolkar","year":"2010","unstructured":"Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010;14(10):1547\u201359.","journal-title":"J Gastrointest Surg"},{"issue":"26","key":"1988_CR37","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.3748\/wjg.v21.i26.8156","volume":"21","author":"TS Su","year":"2015","unstructured":"Su TS, Liang P, Lu HZ, Liang JN, Liu JM, Zhou Y, et al. Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. World J Gastroenterol. 2015;21(26):8156\u201362.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1988_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/COC.0b013e3181d270b4","volume":"34","author":"JC Rwigema","year":"2011","unstructured":"Rwigema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011;34(1):63\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"1988_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","volume":"72","author":"D Schellenberg","year":"2008","unstructured":"Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72(3):678\u201386.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1988_CR40","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/j.prro.2018.08.010","volume":"9","author":"N El-Bared","year":"2019","unstructured":"El-Bared N, Portelance L, Spieler BO, Kwon D, Padgett KR, Brown KM, et al. Dosimetric benefits and practical pitfalls of daily online adaptive MRI-guided stereotactic radiation therapy for pancreatic cancer. Pract Radiat Oncol. 2019;9(1):e46\u201354.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"1988_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","volume":"126","author":"L Henke","year":"2018","unstructured":"Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126(3):519\u201326.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1988_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","volume":"11","author":"MD Chuong","year":"2021","unstructured":"Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, et al. Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer. Pract Radiat Oncol. 2021;11(2):134\u201347.","journal-title":"Pract Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-01988-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-01988-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-01988-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T15:07:01Z","timestamp":1666537621000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-01988-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-01988-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approvals at participating institutions are available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MP received a research grant from SAKK\/Celgene and Viewray. MN receives research grants and speaker fees\/travel support from Brainlab, Novocure, and Viewray. SC receives research grants and speaker fees\/travel support from Elekta, Viewray, C-Rad and Brainlab. J. H.-R.: speaker fees and travel reimbursement from ViewRay Inc. as well as travel reimbursement from IntraOP Medical and Elekta Instrument AB and a grant from IntraOP Medical outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}